Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Treatment discontinuation · HIV‐positive people
Antifungal prophylaxis showed no clear difference in treatment discontinuation compared with no antifungal prophylaxis (moderate certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retention [ · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand placebo or no treatment (moderate certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand PDE5I (low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
1 finding from 1 review